Sep 27 |
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
|
Aug 26 |
Molecular Partners reports 1H results
|
Aug 26 |
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
|
Aug 7 |
Molecular Partners: A Speculative Bet On Innovative DARPin Technology
|
Jun 21 |
Smith & Wesson Brands, Abacus Life And Other Big Stocks Moving Lower In Friday's Pre-Market Session
|
Jun 20 |
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
Jun 17 |
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
|
Jun 14 |
Molecular Partners reports positive preclinical data for first Switch-DARPin candidate
|
Jun 14 |
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
|
Jun 11 |
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
|